Personalizing Your
Cancer Journey
Precision Diagnostics
Who We Are
Qualisure Diagnostics Inc. develops molecular tests that enhance cancer care by identifying features that help oncologists personalize treatment.
Understanding which cancers are indolent or aggressive, and which ones are more likely to respond to certain treatments can guide treatment strategy.
Through innovation and collaboration, we help clinicians decide on the right treatment to provide personalized cancer care to every patient.
Introducing Thyroid GuidePx®
Helping guide your papillary thyroid cancer treatment journey!
Latest News
Notable Early Successes in Precision Oncology: The Breakthroughs That Redefined Cancer Treatment
Introduction Precision oncology began gaining traction in the late 1990s and has since reshaped how we understand and treat cancer. Rather than classifying tumors solely by where they arise in
Prognostic Biomarkers for Papillary Thyroid Cancer: Reducing Overtreatment, Improving Clinical Efficiency, and Enhancing Patient Experience
Abstract Papillary thyroid cancer (PTC), the most prevalent form of thyroid malignancy, is generally indolent but poses a recurrence risk of 10%-15%, leading to a clinical paradox: the need to
Rethinking papillary thyroid cancer: Why “low risk” isn’t always low impact
This article discusses the limitations of current clinicopathologic approaches to risk stratification in papillary thyroid cancer and introduces Thyroid GuidePx® as a molecular diagnostic tool to better predict recurrence risk.
Cancer care through molecular diagnostics: Addressing papillary thyroid cancer
Abstract Cancer care through molecular diagnostics: Addressing papillary thyroid cancer Oliver Bathe from the University of Calgary and Qualisure Diagnostics, walks us through addressing the surge in papillary thyroid cancer
Thyroid GuidePx® is now cited in the 2025 ATA Guidelines.
Thyroid GuidePx® is now cited in the 2025 ATA Guidelines. This recognition highlights the growing role of molecular classifiers in papillary thyroid cancer — providing patient-specific recurrence risk to guide
Prognostication With Thyroid GuidePX® in the Context of Tall Cell Variants
The tall cell variant of papillary thyroid cancer generally has a worse prognosis compared with the classical variant. Thyroid GuidePx is a genomic classifier capable of classifying papillary thyroid cancer into 3 molecular subtypes using fine-needle aspirate. Type 1 and 2 have low recurrence rates, particularly in early tumors (1–4 cm and N0). Type 3 is characterized by aggressive biology and high recurrence rates regardless of size and lymph node status. The study examines the interaction of tall cell variant histology with Thyroid GuidePx risk stratification.